SK Life Science’s XCOPRI Approved for New Treatment for Adults With Partial-Onset Seizures

The FDA approved SK Life’s XCORPI (cenobamate tablets) for treatment of partial-onset seizures in adults.

The approval was based on the results of two studies in which daily doses of XCOPRI reduced the percent of seizures compared with the placebo group.

SK Life Science is the first Korean company to independently bring a compound from discovery to FDA approval. The company is expected to make the drug available in the second quarter of 2020.